ARTICLE | Finance

Basel-based Mysthera Therapeutics AG launched on Tuesday with a $3.5 million seed round from founding investor Forty51 Ventures to advance a pipeline of pan-PIM kinase inhibitors to treat autoimmune diseases. Mysthera in-licensed the program from Inflection Biosciences Ltd., which was co-founded by Mysthera co-founder and CEO Darren Cunningham. The company said PIM kinases drive excessive inflammation in multiple immune cell lineages including B and T effector cells, and may contribute to formation of tertiary lymphoid structures associated with disease severity and progression.

FDA lifted a clinical hold on a Phase Ib study of FTX-6058 from Fulcrum Therapeutics Inc. (NASDAQ:FULC), setting back on course a sickle cell disease therapy that could avoid the access issues of gene therapies for the indication. The trial of the small molecule EED inhibitor, which upregulates fetal hemoglobin expression by downregulating its suppressor genes including BCL11A, was placed on hold due to evidence of hematological malignancies in preclinical data, and in non-clinical and clinical data from other inhibitors of PCR2 — a complex that includes EED. The company has not reported any serious treatment-related adverse events in the study. Fulcrum shares gained $1.51 (39%) to $5.43 on Tuesday...

• SEO Powered Content & PR Distribution. Get Amplified Today.
• PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
• PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
• PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
• PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
• ChartPrime. Elevate your Trading Game with ChartPrime. Access Here.
• BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
• Source: https://www.biocentury.com/article/649010/aug-22-quick-takes-forty51-backed-mysthera-launches-to-development-autoimmune-therapies